Herta M. Crauwels
Beerse, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 59 publications
Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis Data.
Journal: Paediatric drugs
Published: May 05, 2025
Subcutaneous injections of cabotegravir plus rilpivirine long-acting in virally suppressed adults with HIV-1.
Journal: AIDS (London, England)
Published: March 24, 2025
The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South Africans.
Journal: Southern African journal of HIV medicine
Published: February 05, 2025
Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study.
Journal: The British journal of dermatology
Published: November 25, 2024
Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: August 14, 2024
Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants.
Journal: Antimicrobial agents and chemotherapy
Published: December 01, 2023
Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.
Journal: The Journal of infectious diseases
Published: August 25, 2023
Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96.
Journal: HIV medicine
Published: July 06, 2023
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
Journal: Therapeutic advances in infectious disease
Published: June 14, 2023
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: May 23, 2023
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
Journal: The lancet. HIV
Published: May 22, 2023
Last Updated: 09/26/2026